E
Radiopharm Theranostics Limited RADX
$4.71 -$0.48-9.25%
Recommendation
Sell
Prev Close
$5.19
Volume
12,544
Avg Vol (90D)
--
Market Cap
$36.64M
Dividend & Yield
--
52-Week Range
$3.55 - $50.82
P/E (TTM)
--
EPS (TTM)
-$0.0422
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
E+
Very Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Radiopharm Theranostics: Radiotherapeutic Biotech With PD-L1 And HER2 Targeting
3/27/2025 - SeekingAlpha
New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution
3/17/2025 - Globe Newswire
Radiopharm Theranostics Reports Positive Data on RAD202 for HER2-Positive Tumors
3/17/2025 - TipRanks Financial Blog
Radiopharm Theranostics to Present at TD Cowen Healthcare Conference
2/24/2025 - TipRanks Financial Blog
Radiopharm Theranostics to Present at B. Riley Precision Oncology Conference
2/17/2025 - TipRanks Financial Blog
JPMorgan Chase & Co. Acquires Significant Stake in Radiopharm Theranostics Ltd
2/11/2025 - GuruFocus
Radiopharm Theranostics Ltd (RADX) Announces Breakthrough in Brain Metastases Detection
2/10/2025 - GuruFocus
New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases
2/10/2025 - Globe Newswire
Radiopharm Theranostics Unveils Successful Detection of Brain Metastases with RAD 101
2/9/2025 - TipRanks Financial Blog
Lantheus Omega Increases Stake in Radiopharm Theranostics
1/22/2025 - TipRanks Financial Blog
Radiopharm Theranostics Issues New Shares in Compliance with Corporations Act
1/21/2025 - TipRanks Financial Blog
Radiopharm Theranostics Expands Market Presence with New Securities Quotation
1/21/2025 - TipRanks Financial Blog
Radiopharm Theranostics Advances to Phase 1 Clinical Study with Ethics Approval
1/20/2025 - TipRanks Financial Blog
Lantheus increases to 12.16% shareholding in Radiopharm Theranostics
1/10/2025 - SeekingAlpha.com: All News
Lantheus increases to 12.16% shareholding in Radiopharm Theranostics
1/10/2025 - TipRanks Financial Blog
Lantheus increases to 12.16% shareholding in Radiopharm Theranostics
1/10/2025 - The Fly
Radiopharm Theranostics Ltd (RADX) Announces $5 Million Private Placement with Lantheus
1/10/2025 - GuruFocus
Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement
1/10/2025 - Globe Newswire
Radiopharm Strengthens Ties with Lantheus Through $5 Million Investment
1/9/2025 - TipRanks Financial Blog
Radiopharm Theranostics Ltd (RADX) Partners with Lantheus for Radiopharmaceutical Development ...
12/30/2024 - GuruFocus
Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia
12/30/2024 - Globe Newswire
Radiopharm Partners with Lantheus to Advance Oncology Treatments
12/29/2024 - TipRanks Financial Blog
Radiopharm Theranostics receives approval to start Phase 1 trial of RAD 202
12/20/2024 - The Fly
Radiopharm Theranostics Ltd (RADX) Receives Ethics Approval for Phase 1 Trial in Australia
12/20/2024 - GuruFocus
Income Statement
Total Revenue (TTM)
$223.80K
EBITDA (TTM)
-$21.77M
EBIT (TTM)
-$23.79M
Net Income (TTM)
-$27.64M
Balance Sheet
Total Assets (Q)
$57.21M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$25.03M
Book Value Per Share (Q)
$0.015
Cash Flow
Cash from Operations (TTM)
-$22.06M
Cash from Investing (TTM)
$1.98M
Cash from Financing (TTM)
$42.56M
Net Change in Cash (TTM)
$22.79M
Filings
Filing Date
Friday, February 28, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
End of September (est)
Price History
Loading...
Beta
--
7-Day Total Return
-15.14%
30-Day Total Return
1.05%
60-Day Total Return
4.43%
90-Day Total Return
--
Year to Date Total Return
1.51%
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Dec 27, 2024 - $3.55
52-week High
Dec 06, 2024 - $50.82
Valuation
Market Cap
$36.64M - Nano Cap
Enterprise Value
$13.01M
Price/Sales (TTM)
51,900.00
Price/Book (Q)
346.00
Dividends and Shares
Shares Outstanding
1.84B
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.radiopharmtheranostics.com
Phone Number
61 3 9824 5254
Address
62 Lygon Street
Carlton, VIC 3053
Country
Australia
Year Founded
2021
Business Description
Sector
--
Industry
--
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD... more
NASDAQ 04/03/2025 3:59PM Eastern Quotes delayed
Weiss Ratings